Monashee Investment Management LLC Buys New Shares in Humacyte, Inc. $HUMA

Key Points

• Monashee Investment Management LLC has acquired a new stake in Humacyte, buying 2,000,000 shares valued at approximately $3.41 million, now owning 1.29% of the company.
• Humacyte's recent earnings report reflected a loss per share of ($0.24), missing analyst estimates, while revenue was significantly lower than expected.
• Analysts have varying opinions on Humacyte, with a consensus rating of "Buy", although several have recently lowered their price targets for the stock.

Monashee Investment Management LLC bought a new stake in Humacyte, Inc. (NASDAQ:HUMA - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 2,000,000 shares of the company's stock, valued at approximately $3,410,000. Monashee Investment Management LLC owned 1.29% of Humacyte at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the company. Beacon Pointe Advisors LLC grew its stake in Humacyte by 33.3% during the 4th quarter. Beacon Pointe Advisors LLC now owns 20,000 shares of the company's stock valued at $101,000 after purchasing an additional 5,000 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Humacyte by 20.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 33,870 shares of the company's stock valued at $172,000 after buying an additional 5,801 shares in the last quarter. ProShare Advisors LLC lifted its stake in Humacyte by 30.4% in the 4th quarter. ProShare Advisors LLC now owns 30,852 shares of the company's stock valued at $156,000 after buying an additional 7,188 shares in the last quarter. Cetera Investment Advisers lifted its stake in Humacyte by 48.7% in the 4th quarter. Cetera Investment Advisers now owns 27,880 shares of the company's stock valued at $141,000 after buying an additional 9,134 shares in the last quarter. Finally, XTX Topco Ltd lifted its stake in Humacyte by 22.5% in the 1st quarter. XTX Topco Ltd now owns 53,797 shares of the company's stock valued at $92,000 after buying an additional 9,868 shares in the last quarter. Hedge funds and other institutional investors own 44.71% of the company's stock.

Humacyte Trading Up 2.2%

HUMA opened at $1.63 on Thursday. The company has a debt-to-equity ratio of 2.97, a current ratio of 2.45 and a quick ratio of 1.93. The company's 50 day simple moving average is $2.26 and its two-hundred day simple moving average is $2.40. Humacyte, Inc. has a 1-year low of $1.15 and a 1-year high of $7.48. The firm has a market capitalization of $252.85 million, a price-to-earnings ratio of -3.62 and a beta of 1.90.

Humacyte (NASDAQ:HUMA - Get Free Report) last released its earnings results on Monday, August 11th. The company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.09). The business had revenue of $0.30 million for the quarter, compared to analyst estimates of $0.94 million. Analysts expect that Humacyte, Inc. will post -1.27 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Laura E. Niklason sold 591,685 shares of the firm's stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $1.58, for a total transaction of $934,862.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Brady W. Dougan sold 591,685 shares of the firm's stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $1.58, for a total transaction of $934,862.30. The disclosure for this sale can be found here. Insiders have sold a total of 4,482,090 shares of company stock valued at $7,466,382 in the last 90 days. Insiders own 5.10% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on HUMA. TD Cowen decreased their price target on shares of Humacyte from $5.00 to $3.50 and set a "buy" rating on the stock in a research note on Tuesday, August 12th. D. Boral Capital reaffirmed a "buy" rating and issued a $25.00 price target on shares of Humacyte in a research note on Monday, August 11th. Benchmark decreased their price target on shares of Humacyte from $17.00 to $14.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th. Wall Street Zen lowered shares of Humacyte from a "hold" rating to a "sell" rating in a research note on Sunday. Finally, HC Wainwright decreased their price target on shares of Humacyte from $4.00 to $3.00 and set a "buy" rating on the stock in a research note on Tuesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat, Humacyte presently has a consensus rating of "Buy" and an average target price of $10.64.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.